{
    "clinical_study": {
        "@rank": "72022", 
        "arm_group": {
            "arm_group_label": "Cisplatin + Radiation Therapy", 
            "arm_group_type": "Experimental", 
            "description": "Cisplatin concurrently with radiation therapy"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients\n      with ER negative, PR negative and HER2 negative breast cancer who have undergone\n      breast-conserving surgery or mastectomy.\n\n      Primary objective:  To assess the safety, tolerability, and maximum tolerated dose (MTD) of\n      cisplatin when given concurrently with radiation therapy for participants with Stage II or\n      III breast cancer who have undergone breast conserving surgery or mastectomy"
        }, 
        "brief_title": "Cisplatin + RT for Triple Negative Breast Cancer", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a phase I dose escalation  study of cisplatin and radiation to determine the\n      toxicity of this combined treatment and establish an MTD."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Primary tumor is triple negative breast cancer\n\n          -  Breast-conserving surgery or mastectomy with surgical excision of all gross disease\n             with negative surgical margins\n\n          -  Pathologic or clinical stage II or III disease\n\n          -  At least 3 week interval from last chemotherapy administration/breast surgery to\n             radiation (no more than 8 weeks)\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding\n\n          -  Prior radiation to breast or ipsilateral regional nodes\n\n          -  Ongoing therapy with other investigational agents\n\n          -  Hormonal therapy\n\n          -  Significant co-morbidity\n\n          -  Pathologic complete response following preoperative chemotherapy\n\n          -  Biopsy proven metastatic disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674842", 
            "org_study_id": "12-283"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cisplatin + Radiation Therapy", 
                "description": "Once daily, Monday - Friday for six weeks", 
                "intervention_name": "Radiation Therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Cisplatin + Radiation Therapy", 
                "description": "Intravenously, once weekly for six weeks", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug", 
                "other_name": "CDDP"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cisplatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Triple negative", 
            "Stage II", 
            "Stage III"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jbellon@partners.org", 
                    "last_name": "Jennifer Bellon, MD", 
                    "phone": "617-632-3591"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Jennifer Bellon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jbellon@partners.org", 
                    "last_name": "Jennifer Bellon, MD", 
                    "phone": "617-632-3591"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Brigham and Women's Hospital"
                }, 
                "investigator": {
                    "last_name": "Jennifer Bellon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sisakoff@partners.org", 
                    "last_name": "Steven J Isakoff, MD PHD", 
                    "phone": "617-726-6500"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tlingos@partners.org", 
                    "last_name": "Tatiana Lingos, MD", 
                    "phone": "508-488-3835"
                }, 
                "facility": {
                    "address": {
                        "city": "Milford", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01757"
                    }, 
                    "name": "Dana-Farber at Milford"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tlingos@partners.org", 
                    "last_name": "Tatiana Lingos, M.D.", 
                    "phone": "781-624-4700"
                }, 
                "facility": {
                    "address": {
                        "city": "Weymouth", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02190"
                    }, 
                    "name": "Dana Farber at South Shore Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer", 
        "overall_contact": {
            "email": "jbellon@partners.org", 
            "last_name": "Jennifer Bellon, MD", 
            "phone": "6176323591"
        }, 
        "overall_official": {
            "affiliation": "Dana-Farber Cancer Institute", 
            "last_name": "Jennifer R Bellon, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the maximum tolerated dose of cisplatin when given concurrently with radiation therapy for participants with Stage II or III breast cancer who have undergone breast conserving surgery or mastectomy.", 
            "measure": "Safety of Cisplatin w/ Radiation", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674842"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dana-Farber Cancer Institute", 
            "investigator_full_name": "Jennifer Bellon", 
            "investigator_title": "Principal Invstigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess local recurrence at 5-years in participants receiving cisplatin concurrently with radiation, as compared with historic controls receiving radiation without concurrent chemotherapy.", 
                "measure": "Local recurrence at 5 years", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "To assess long-term toxicity in participants receiving cisplatin concurrently with radiation", 
                "measure": "Long term toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Dana-Farber Cancer Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dana-Farber Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}